Overview

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency.
Phase:
Phase 2
Details
Lead Sponsor:
BioCryst Pharmaceuticals
Treatments:
Allopurinol
Uric Acid